Method for researching pharmacodynamic material basis and action mechanism of renal failure recovery granules

Abstract

The invention relates to the technical field of medicine analysis, in particular to a method for researching the pharmacodynamic material basis and action mechanism of renal failure recovery granules. The method comprises the following steps: S1, detecting blood entering components of the renal failure recovery granules; s2, screening intersection targets of the blood entering components of the renal failure complex granules and the renal failure; s3, constructing a protein interaction network, and screening core targets of the renal failure complex granules for treating chronic renal failure; s4, carrying out GO and KEGG enrichment analysis on the core target spot; and S5, carrying out molecular docking by taking the blood entering component of the renal failure complex granules as a ligand and taking the core target as a receptor. According to the method, the blood entering components of the renal failure complex granules are detected, then the material basis and the action mechanism of the renal failure complex granules for treating the CRF are clarified through network pharmacology and molecular docking technologies, and a basis is provided for further research and clinical application of the renal failure complex granules for treating the CRF.

Description

Technical Field

[0001] The invention relates to the technical field of drug analysis, and in particular to a method for studying the material basis and action mechanism of Shenshuai Fu Granules. Background Art

[0002] Chronic renal failure (CRF) refers to progressive renal parenchymal damage caused by various chronic kidney diseases, which is manifested as obvious renal atrophy and loss of basic functions, resulting in the inability to excrete metabolic waste and excess water in the body normally, triggering a clinical syndrome of a series of metabolic disorders and multi-system symptoms. According to data provided by the International Society of Nephrology (ISN), the annual incidence of CRF in the natural population is approximately 98 to 198 cases per million people. At the same time, with the improvement of people's living standards, the incidence of CRF is increasing every year, and the cost of treatment is also increasing, which puts significant pressure on the national medical budget. The treatment strategies for CRF mainly include drug therapy, hemodialysis, peritoneal dialysis and kidney transplantation. However, dialysis treatment and kidney transplantation are not only expensive, but also have limited kidney donor resources, which brings significant economic pressure to many patients. Therefore, for patients with early and mid-stage CRF, drug therapy has become the main treatment method to control the progression of the disease.

[0003] Traditional Chinese medicine has shown unique advantages and potential in the early prevention and delay of renal damage. Shenshuai Fu Granules are composed of Astragalus membranaceus (Fisch.) Bunge, Salvia miltiorrhiza Bunge, Rheum palmatum L., Leonurus japonicus Houtt, Lyciumchinense Miller, etc. "Analysis of the Clinical Efficacy of Shenshuai Fu Granules in the Treatment of Chronic Renal Failure" records that it is used for chronic renal failure and early uremia caused by various reasons based on the principles of tonifying the kidney and spleen, replenishing qi and nourishing yin, and promoting blood circulation and removing blood stasis, and has achieved relatively ideal therapeutic effects. It can be used as an effective therapeutic drug to delay the progression of renal failure in patients with CRF.

[0004] Studies have reported that wolfberry and its extracts can show therapeutic potential for kidney diseases through various mechanisms, including improving renal function indicators, anti-oxidation, anti-inflammation, regulating oxidative stress and antioxidant enzymes, and protecting renal tissue. Salvia miltiorrhiza can reduce ROS levels by regulating the NADPH oxidase signaling pathway, thereby alleviating kidney damage. It can also regulate signaling pathways related to renal fibrosis and inflammation, including the transforming growth factor β (TGF-β) / Smad signaling pathway, and has a significant protective effect on chronic renal failure. Poria cocos and its surface improve kidney diseases through various molecular mechanisms, including activated RAS, MMP, AHR, AMPK, TPH-1, aquaporin-2 and SGK1 molecules, and regulating TGF-β1 / Smad, Wnt / β-catenin, IκB / NF-κB and Keap1 / Nrf2 signaling pathways. At present, there are many clinical studies on Shenshuai Fu Granules, but there are few studies on the chemical composition analysis of the preparations. At the same time, there is no research on the blood-entering components, and the material basis of the efficacy is still unclear. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide a method for studying the material basis and action mechanism of the Shenshuai Fu Granules.

[0006] In order to solve the above technical problems, the technical solution adopted by the present invention is: A method for studying the material basis and mechanism of action of Shenshuai Fu Granules, comprising the following steps: S1: Detect the blood components of Shenshuaifu Granules; S2: Screening of targets that intersect with renal failure and the components of Shenshuaifu Granules that enter the blood; S3: Construct protein interaction network and screen core targets of Shenshuaifu Granules for the treatment of chronic renal failure; S4: GO and KEGG enrichment analysis was performed on the core targets; S5: Construction of the “blood-entering component-target-pathway” network; S5: Molecular docking was performed using the blood-entering components of Shenshuai Fu Granules as ligands and the core target as receptors.

[0007] The beneficial effect of the present invention is that the present invention detects the blood-entering components of Shenshuai Fu Granules, and then clarifies the material basis and mechanism of action of Shenshuai Fu Granules in treating CRF through network pharmacology and molecular docking technology, providing a basis for further research and clinical application of Shenshuai Fu Granules in treating CRF. BRIEF DESCRIPTION OF THE DRAWINGS

[0008] Figure 1 The total ion current diagram of Shenshuaifu Granule in the positive and negative ion modes in the embodiment of the present invention; Figure 2This is the total ion current diagram of Shenshuai Fu Granule drug-containing serum in positive and negative ion modes in an embodiment of the present invention; Figure 3 The Venn diagram and disease targets of the prototype compound of Shenshuaifu Granule in the embodiment of the present invention in rat plasma; Figure 4 This is a PPI network diagram of potential targets of Shenshuaifu Granule for treating chronic renal failure in an embodiment of the present invention; Figure 5 This is a KEGG enrichment analysis diagram of Shenshuai Fu Granule for chronic renal failure in an embodiment of the present invention; Figure 6 This is a gene ontology enrichment analysis diagram of Shenshuaifu Granule against chronic renal failure in the embodiment of the present invention Figure 7 This is a “composite targeting-pathway-disease” network diagram of Shenshuaifu Granules for treating chronic renal failure in an embodiment of the present invention; Figure 8 Schematic diagram of the active cavity for docking different target molecules with cryptotanshinone in the embodiments of the present invention. DETAILED DESCRIPTION

[0009] In order to explain the technical content, achieved objectives and effects of the present invention in detail, the following is an explanation in combination with the implementation modes and the accompanying drawings.

[0010] Please refer to Figure 1 as well as Figure 2 , a method for studying the material basis and mechanism of action of Shenshuai Fu Granules, comprising the following steps: S1: Detect the blood components of Shenshuaifu Granules; S2: Screening of targets that intersect with renal failure and the components of Shenshuaifu Granules that enter the blood; S3: Construct protein interaction network and screen core targets of Shenshuaifu Granules for the treatment of chronic renal failure; S4: GO and KEGG enrichment analysis of core targets; S5: Molecular docking was performed using the blood-entering components of Shenshuai Fu Granules as ligands and the core target as receptors.

[0011] From the above description, it can be seen that the beneficial effects of the present invention are: Chinese medicine compound treatment of diseases has the characteristics of multiple components, multiple targets and multiple pathways, and its mechanism of action cannot be fully explained from a single target and a single pathway. The development of system biology represented by network pharmacology has provided a new idea and method for exploring the mechanism of Chinese medicine treatment of diseases. Serum pharmacological chemistry believes that the pharmacological substances of oral drugs must enter the blood circulation to exert pharmacological effects, so the present invention uses blood-entering components as pharmacological substances for network pharmacology research, which will be more objective and rigorous.

[0012] The present invention detects the components of Shenshuai Fu Granule entering the blood, and then clarifies the material basis and mechanism of action of Shenshuai Fu Granule in treating CRF through network pharmacology and molecular docking technology. The analysis method is accurate and easy to operate, and provides a basis for further research and clinical application of Shenshuai Fu Granule in treating CRF.

[0013] Furthermore, S1 specifically comprises: administering kidney failure complex granules dissolved in deionized water to rats, and then collecting whole blood plasma, mixing the plasma and methanol, centrifuging, taking the supernatant, drying, and then adding methanol for re-dissolution, centrifuging again, taking the supernatant, and injecting it into the UPLC-Q-Exactive MS system for analysis to obtain the blood components of the kidney failure complex granules.

[0014] Furthermore, S2 is specifically as follows: according to the blood component information of Shenshuai Fu Granules, the relevant action targets of the blood components are collected, and then converted into gene symbols to obtain the disease targets of chronic renal failure.

[0015] Furthermore, S2 is specifically as follows: inputting the blood component information of Shenshuai Fu Granules into the Swiss TargetPrediction database to collect the blood component-related targets; converting the blood component-related targets into gene symbols through the Uni Prot database; and then using "chronic renal failure" as the search term, inputting into the Gene Cards database to obtain the disease targets of chronic renal failure.

[0016] Furthermore, S3 is specifically as follows: making a Venn diagram to obtain the common potential targets of Shenshuaifu Granules entering the blood and chronic renal failure, constructing a protein interaction network, and then visualizing it, using degree value, betweenness value and shortest path value as indicators to screen out the core targets of Shenshuaifu Granules for the treatment of chronic renal failure.

[0017] Furthermore, S3 is as follows: use Venny 2.1.0 to make a Venn diagram online, obtain the common potential targets of Shenshuaifu Granules entering the blood and chronic renal failure, and construct a protein interaction network through the String database; import the construction results into the cytoscope 3.5.1 software for visualization, and use the centiscape plug-in to screen out the core targets of Shenshuaifu Granules for the treatment of chronic renal failure with degree value, betweenness value and shortest path value as indicators.

[0018] Furthermore, S4 is as follows: the core targets of Shenshuai Fu Granules in the treatment of chronic renal failure were input into the DAVID database, GO and KEGG enrichment analysis was performed, and then P<0.05 was used as the screening condition to screen out the top 10 biological processes, cellular components and molecular functions and the top 20 key signaling pathways.

[0019] Furthermore, S5 is specifically as follows: the top 20 pathways ranked by KEGG pathway analysis, the top 9 blood-entering components of Shenshuai Fu Granules, and potential core targets are imported into Cytoscape software to obtain a "blood-entering component-target-pathway" network.

[0020] Furthermore, S6 is specifically as follows: using the blood-entering components of Shenshuai Fu Granules as ligands and the top 10 key targets as receptors, the 2D structure of the ligand is obtained to achieve molecular docking.

[0021] Furthermore, S6 is specifically as follows: using the blood-entering components of Shenshuai Fu Granules as ligands, and the top 10 key targets as receptors, using the PDB database to download the molecular structure files of the receptors, using the PubChem database to download the 2D structure of the ligands, and using Auto Dock Vina software to achieve molecular docking.

[0022] Furthermore, before S1, it also includes the step of performing UPLC-QE-MS detection on the Shenshuaifu Granule test solution and establishing a database of drug chemical components.

[0023] From the above description, it can be seen that UPLC-QE-MS detection has higher sensitivity and faster analysis speed, and is suitable for high-sensitivity quantitative analysis of target compounds, especially the detection of low-concentration compounds in complex matrices.

[0024] Embodiment 1 of the present invention is: a method for studying the material basis and mechanism of action of Shenshuai Fu Granules.

[0025] 1 Materials 1.1 Experimental animals Six SPF male SD rats, 6-8 weeks old, weighing 180-220 g, were housed in the Animal Experiment Center of Guangdong University of Traditional Chinese Medicine, City Hospital, with animal production license number SCXK (Yue) 2022-0063. The housing temperature was 20-26 °C, the humidity was 30%-70%, the lighting was alternating 12 h / 12 ​​h day and night, and the illumination was 15-20 lx. This study was approved by the Animal Ethics Committee of Guangzhou University of Chinese Medicine, ethics number: 2022038.

[0026] 1.2 Medicinal materials and reagents Shenshuaifu Granules were provided by the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, methanol (chromatographically pure, CNW Technologies, Germany, batch number 67-56-1); acetonitrile (chromatographically pure, CNW Technologies, Germany, batch number 75-05-8); formic acid (chromatographically pure, Sigma, USA, batch number 64-18-6) 1.3 Experimental instruments UltiMate™ 3000 RSLCnano ultra-high performance liquid phase, Q Exactive Focus (Thermo Fisher Scientific, USA); ACQUITY UPLC BEH C18 column (Waters, USA) 2. Experimental Methods 2.1 Study on the chemical composition of Shenshuaifu granules 2.1.1 Preparation of Shenshuaifu Granule Test Solution Grind and crush the Shenshuai complex granules to weigh 1 g, add 20 mL of 70% methanol, dissolve under ultrasonication for 20 min, centrifuge at 12 000×g for 10 min, take the supernatant, filter with a 0.22 μm microporous membrane, and store the filtrate at 4°C for testing.

[0027] 2.1.2 Ultra-high performance liquid chromatography tandem quadrupole electrostatic field orbitrap mass spectrometry (UPLC-QE-MS) detection Chromatographic separation was performed on a Waters UPLC BEH C18 column (1.7 μm, 2.1 mm×100 mm) at a flow rate of 0.3 ml / min and 30°C. The injection volume was 2 μL. The mobile phase contained 0.1% formic acid in water (A) and acetonitrile (B). The following gradient elution program was used for chromatographic separation: 0-2 min, 5%-25% B; 2-4 min, 15%-50% B; 4-11 min, 50%-90% B; 11-13 min, 90%-99% B. The primary and secondary mass spectrometric data were collected using a Q Exactive Focus mass spectrometer. The specific parameters were as follows: sheath gas was 45 Arb, auxiliary gas was 15 Arb, ion transfer tube temperature was 350 °C, Full MS resolution was 70 000, MS / MS resolution was 17 500, collision energy (in NCE mode) was 15 / 30 / 45, and spray voltage was 4.0 kV (positive ion mode) or -4.0 kV (negative ion mode).

[0028] A database of chemical components of renal failure was established by searching PubMed (https: / / pubmed.ncbi.nlm.nih.gov / ), Web of Science (https: / / www.webofscience.com / wos / ), China National Knowledge Infrastructure (https: / / c61.oversea.cnki.net / ) and other related databases. The database included compound names, chemical formulas, quasi-molecular ion peaks and secondary mass spectrometry information. The experimental data were processed using Xcalibur software (Thermo Fisher Scientific, USA) and Progenesis QI (Waters, USA).

[0029] Total ion current diagram of Shenshuaifu granules in positive and negative ion modes, see Figure 1 , Figure 1 A is the positive ion mode, and B is the negative ion mode. Xcalibur software (Thermo Fisher Scientific, USA) and Progenesis QI (Waters, USA) software were used to analyze the primary and secondary mass spectra of Shenshuaifu granules, and the precise molecular weight and mass spectrometry fragmentation rules of the compounds were compared with them to infer and identify the target compounds. In the mode of simultaneous positive and negative ion scanning, a total of 103 chemical components were identified in Shenshuaifu granules, of which 62 were identified in the positive ion detection mode and 70 were identified in the negative ion detection mode (part of the chemical components are shown in Tables 1 and 2). Based on the comprehensive chromatography-mass spectrometry detection information, the 103 chemical components were classified. Among them, there were 23 phenolic acid components, 20 flavonoid components, 14 triterpenoid components, 13 anthraquinone components, 13 saponin components, and 20 other components.

[0030] Table 1

[0031] Table 2

[0032] 2.2 Study on blood components Six SD male rats were randomly divided into a blank serum group and a drug-containing serum group, with 3 rats in each group. They were fasted but not watered 12 h before the experiment. The rats in the drug-containing serum group were given Shenshuai Fu Granules dissolved in deionized water at a dose of g / kg, and the blank serum group was given an equal volume of normal saline. Two hours after the administration, 2% sodium pentobarbital 40 mg / kg was intraperitoneally injected to deeply anesthetize the rats, and whole blood was collected from the abdominal aorta, allowed to stand, centrifuged, and the supernatant was taken and stored in a -80℃ refrigerator for later use.

[0033] 200 μL plasma and 800 μL methanol were added to a 1.5 ml EP tube and vortexed for 3 min. Then, the tube was centrifuged at 12,000 rpm for 15 min at 4°C, and the supernatant was transferred to a new 1.5 ml EP tube and dried by nitrogen blowing. 100 μL methanol was added for reconstitution, and the tube was centrifuged at 12,000 rpm for 15 min at 4°C. 90 μL supernatant was taken and tested in an injection bottle. 5 μL supernatant was injected into the UPLC-Q-Exactive MS system for analysis. The gradient elution process was the same as that of the chemical composition study of conditional renal failure complex particles.

[0034] By comparing the data of Shenshuai Fu Granule samples, blank serum and drug-containing serum samples, the endogenous components in the blank serum were eliminated, and the components that existed in both Shenshuai Fu Granule samples and drug-containing serum samples were identified as blood-entering components. In the mode of simultaneous positive and negative ion scanning, a total of 12 blood-entering components were identified from Shenshuai Fu Granule drug-containing serum (see Table 3 and Figure 2 ). Among them, there are 3 quinone compounds, 2 flavonoids, phenols, alkaloids and terpenes, and 1 coumarin.

[0035] Table 3

[0036] This study is the first to use UHPLC-QE-MS technology to qualitatively identify 103 chemical components in Shenshuaifu Granules and 12 components absorbed in rat blood, laying a foundation for the quality control of Shenshuaifu Granules in the future. Among them, the components that enter the blood may be the important active ingredients of Shenshuaifu Granules in the treatment of chronic renal failure.

[0037] 2.3 Network pharmacology analysis 2.3.1 Screening of targets for intersection between blood components of Shenshuaifu Granule and renal failure The blood component information of Shenshuaifu Granule was input into the Swiss Target Prediction database (http: / / www.swisstargetprediction.ch / ) to collect the blood component related action targets. The blood component targets were converted into Gene Symbols through the Uni Prot database (https: / / www.uniprot.org / ). Using "chronic renal failure" as the search term, the Gene Cards database (https: / / www.genecards.org / ) was entered to obtain the disease targets of chronic renal failure.

[0038] A search in the Swiss Target Prediction database revealed 274 targets for the blood-entering components of Shenshuai Fu Granules, and a search in the Gene Cards database revealed 5430 targets related to chronic renal failure.

[0039] 2.3.2 Construction of protein-protein interaction (PPI) network The Venn diagram was made online using Venny 2.1.0 (https: / / bioinfogp.cnb.csic.es / tools / venny / index.html) to obtain the common potential targets of Shenshuaifu Granules and chronic renal failure, and the PPI network was constructed through the String (https: / / www.stringdb.org / ) database. The above results were imported into cytoscope 3.5.1 software for visualization, and the centiscape plug-in was used to screen out the core targets of Shenshuaifu Granules for the treatment of chronic renal failure with degree, betweenness and closeness as indicators.

[0040] like Figure 3 , a total of 209 common potential targets for Shenshuaifu Granule blood components and chronic renal failure were obtained. In the PPI network, the larger the size of the node and the redder the color of the node, the more important the gene. Figure 4 A total of 39 core targets were obtained, among which TNF, SRC, STAT3, EGFR, BCL2, JUN, PTGS2, ESR1, HSP90AA1, and MMP9 ranked at the top, which may be the key targets of Shenshuai Fu Granules in the treatment of chronic renal failure.

[0041] 2.3.3GO and KEGG enrichment analysis The core targets of Shenshuaifu Granules in the treatment of chronic renal failure were entered into the DAVID database (https: / / david.ncifcrf.gov / ) for GO and KEGG enrichment analysis. With P < 0.05 as the screening condition, the top 10 biological processes (BP), cellular components (CC) and molecular functions (MF) and the top 20 key signaling pathways were screened out. Figure 5 The top 20 signaling pathways are mainly enriched in EGFR tyrosine kinase inhibitor resistance, ErbB signaling pathway, AGE-RAGE signaling pathway in diabetic complications, HIF-1 signaling pathway, etc. The GO and KEGG enrichment analysis was visualized through the Micro-Bioinformatics platform (https: / / www.bioinformatics.com.cn / ), and the processing results are as follows Figure 6 As shown, KEGG enrichment analysis obtained 166 entries.

[0042] 2.3.4 Construction of the “Blood Component-Target-Pathway” Network The top 20 pathways ranked by KEGG pathway analysis, the top 9 blood-entering components of Shenshuaifu Granules, and potential core targets were imported into Cytoscape software to obtain the “blood-entering component-target-pathway” network (see Figure 7 , Tables 4 and 5). The results showed that alismatol C-23-acetate, chrysophanol, cryptotanshinone, calycosin and caffeic acid were the five core compounds in the blood-entering components of Shenshuai Fu Granules that could resist chronic renal failure. The chemical structures of the five potential active compounds are shown in Table 6.

[0043] Table 4

[0044] Table 5

[0045] Table 6

[0046] 2.3.5 Molecular docking The five blood-entering components of Shenshuai Fu Granules were used as ligands, and the top 10 key targets TNF, SRC, STAT3, EGFR, BCL2, JUN, PTGS2, ESR1, HSP90AA1, and MMP9 were used as receptors. The molecular structure files of the receptors were downloaded from the PDB database, and the 2D structure of the ligands was downloaded from the PubChem database. The molecular docking was performed using the Auto Dock Vina software. The binding activity was determined based on the binding energy. The lower the binding energy, the stronger the binding ability. Among them, the binding energy of most compounds was even lower than -7 kcal / mol, indicating that these compounds had a close binding relationship with the 10 core targets. For example Figure 8 The blood-entering component cryptotanshinone of Shenshuai Fu Granule binds well to the core protein target. Figure 8 (A) The docking results of cryptotanshinone as a BCL2 inhibitor; (B) The docking results of cryptotanshinone as a TNF inhibitor; (C) The docking results of cryptotanshinone as a STAT3 inhibitor.

[0047] In summary, the method provided by the present invention for studying the material basis and mechanism of action of Shenshuai Fu Granules for the efficacy is used to identify the chemical components and blood-entering components of Shenshuai Fu Granules for the first time by UHPLC-QE-MS, and the material basis and mechanism of action of Shenshuai Fu Granules for the treatment of CRF are clarified by network pharmacology and molecular docking technology, which provides a basis for further research and clinical application of Shenshuai Fu Granules for the treatment of CRF.

[0048] The above descriptions are merely embodiments of the present invention and are not intended to limit the patent scope of the present invention. Any equivalent transformations made using the contents of the present invention's specification and drawings, or directly or indirectly applied in related technical fields, are also included in the patent protection scope of the present invention.

Claims

1. A method for studying the material basis and mechanism of action of Shenshuai Fu Granules, characterized in that: The following steps are involved: S1: Detect the blood components of Shenshuaifu Granules; S2: Screening of targets that intersect with renal failure and the components of Shenshuaifu Granules that enter the blood; S3: Construct protein interaction network and screen core targets of Shenshuaifu Granules for the treatment of chronic renal failure; S4: GO and KEGG enrichment analysis was performed on the core targets; S5: Construction of the "blood-entering components-targets-pathways" network; S6: Molecular docking was performed using the blood-entering components of Shenshuai Fu Granules as ligands and the core target as receptors.

2. The method for studying the drug efficacy material basis and mechanism of action of Shenshuai Fu Granule according to claim 1, characterized in that: Specifically, S1 comprises: administering kidney failure complex granules dissolved in deionized water to rats, and then collecting whole blood plasma, mixing the plasma with methanol and centrifuging the mixture, taking the supernatant and drying it, and then adding methanol to re-dissolve it, centrifuging it again, taking the supernatant and injecting it into the UPLC-Q-Exactive MS system for analysis, so as to obtain the blood components of the kidney failure complex granules.

3. The method for studying the drug efficacy material basis and action mechanism of Shenshuai Fu Granule according to claim 1, characterized in that: The S2 is specifically as follows: according to the blood component information of Shenshuai Fu Granule, relevant action targets of the blood components are collected, and then converted into gene symbols to obtain disease targets of chronic renal failure.

4. The method for studying the drug efficacy material basis and mechanism of action of Shenshuai Fu Granule according to claim 3, characterized in that: The S2 is specifically as follows: inputting the blood component information of Shenshuai Fu Granule into the Swiss Target Prediction database to collect the blood component related action targets; converting the blood component related action targets into gene symbols through the Uni Prot database; and then using "chronic renal failure" as the search term, inputting into the Gene Cards database to obtain the disease targets of chronic renal failure.

5. The method for studying the drug efficacy material basis and mechanism of action of Shenshuai Fu Granule according to claim 1, characterized in that: The S3 is specifically as follows: making a Venn diagram to obtain the common potential targets of Shenshuaifu Granules entering the blood and chronic renal failure, constructing a protein interaction network, and then visualizing it, using degree value, betweenness value and shortest path value as indicators to screen out the core targets of Shenshuaifu Granules for treating chronic renal failure.

6. The method for studying the drug efficacy material basis and mechanism of action of Shenshuai Fu Granule according to claim 5, characterized in that: The S3 specifically includes: using Venny 2.1.0 to make a Venn diagram online, obtaining the common potential targets of Shenshuaifu Granules and chronic renal failure, and constructing a protein interaction network through the String database; importing the construction results into cytoscope 3.5.1 software was used for visualization, and the centiscape plug-in was used to screen out the core targets of Shenshuaifu Granules for the treatment of chronic renal failure based on degree value, betweenness value and shortest path value.

7. The method for studying the drug efficacy material basis and mechanism of action of Shenshuai Fu Granule according to claim 1, characterized in that: The S4 is specifically as follows: the core action targets of Shenshuai Fu Granules in treating chronic renal failure are input into the DAVID database, GO and KEGG enrichment analysis is performed, and then P<0.05 is used as the screening condition to screen out the top 10 biological processes, cellular components and molecular functions and the top 20 key signaling pathways.

8. The method for studying the drug efficacy material basis and mechanism of action of Shenshuai Fu Granule according to claim 1, characterized in that: The S6 is specifically as follows: using the blood-entering components of Shenshuai Fu Granules as ligands and the top 10 key targets as receptors to obtain the 2D structure of the ligand and achieve molecular docking.

9. The method for studying the drug efficacy material basis and mechanism of action of Shenshuai Fu Granule according to claim 8, characterized in that: The S6 specifically includes: using the blood-entering components of Shenshuai Fu Granules as ligands, the top 10 key targets as receptors, using the PDB database to download the molecular structure files of the receptors, using the PubChem database to download the 2D structure of the ligands, and using AutoDock Vina software to achieve molecular docking.

10. The method for studying the material basis and mechanism of action of Shenshuai Fu Granules according to claim 1, characterized in that: Before S1, the method also includes the step of performing UPLC-QE-MS detection on the Shenshuai Fu Granule test solution to establish a database of drug chemical components.

Images